Back to top
more

Penumbra, Inc. (PEN)

(Delayed Data from NYSE)

$284.70 USD

284.70
332,629

-4.24 (-1.47%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 253)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Looking for a Growth Stock? 3 Reasons Why Penumbra (PEN) is a Solid Choice

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 625.00% and 1.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Penumbra (PEN) This Earnings Season?

Penumbra (PEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Kevin Cook headshot

Bear of the Day: Penumbra (PEN)

Revolutionary catheter-based treatment for stroke events encounters device problems and a recall

Penumbra (PEN) Q3 Earnings and Revenues Surpass Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 146.15% and 20.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Q3 Earnings on Oct 28: BSX, CERN & More

In Q3, Medical Product stocks are expected to have gained from gradual lifting of restrictions in many states and regions. However, international sales might have been dampened.

Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra (PEN) Reports Q2 Loss, Tops Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 37.50% and 6.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Penumbra (PEN) Q2 Earnings Expected to Decline

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Impinj, Penumbra, Microsoft, Apple and Amazon highlighted as Zacks Bull and Bear of the Day

Impinj, Penumbra, Microsoft, Apple and Amazon highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bear of the Day: Penumbra (PEN)

Growth stalls for an innovator in blood clot removal and the deadly shadow of stroke with catheter-based aspiration technologies

Trina Mukherjee headshot

Medical Products Stock Earnings on May 7: BDX, ABC & More

Medical Product companies have partially mitigated the impact of the pandemic with the massive adoption of COVID-19 related healthcare-support products and services.

Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra (PEN) Gains But Lags Market: What You Should Know

Penumbra (PEN) closed at $181.06 in the latest trading session, marking a +0.93% move from the prior day.

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

This $5 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies

Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down

The coronavirus outbreak had an immaterial impact on Walgreens Boots' (WBA) second-quarter fiscal 2020 results.

Bruker (BRKR) Q4 Earnings Miss Estimates, Revenues Beat

Bruker's (BRKR) fourth-quarter 2019 results reflect strong performances by the majority of its segments and geographies.

Benjamin Rains headshot

Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now

DexCom shares have soared 45% since March 18. The connected glucose monitoring systems firm is also expected to continue to grow and DXCM stock might be somewhat immune to the current coronavirus economic uncertainty...

Here is Why Growth Investors Should Buy Penumbra (PEN) Now

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Penumbra (PEN) Q4 Earnings Beat Estimates, Margins Expand

Penumbra (PEN) registers balanced segmental growth across all geographies in Q4.

Penumbra (PEN) Tops Q4 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 22.22% and 2.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates

Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.

Penumbra (PEN) Beats Q3 Earnings and Revenue Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 38.89% and 4.59%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Medical Products' Nov 7 Earnings Roster: ABC, CAH & More

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.